Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism

Thibaut Duparc; Hubert Plovier; Vannina G Marrachelli; Matthias Van Hul; Ahmed Essaghir; Marcus Ståhlman; Sébastien Matamoros; Lucie Geurts; Mercedes M Pardo-Tendero; Céline Druart; Nathalie M Delzenne; Jean-Baptiste Demoulin; Schalk W van der Merwe; Jos van Pelt; Gert Fredrik Bäckhed; Daniel Monleon; Amandine Everard; Patrice D Cani

doi:10.1136/gutjnl-2015-310904

Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism

Thibaut Duparc, Hubert Plovier, Vannina G Marrachelli, Matthias Van Hul, Ahmed Essaghir, Marcus Ståhlman, Sébastien Matamoros, Lucie Geurts, Mercedes M Pardo-Tendero, Céline Druart, Nathalie M Delzenne, Jean-Baptiste Demoulin, Schalk W van der Merwe, Jos van Pelt, Gert Fredrik Bäckhed, Daniel Monleon, Amandine Everard, Patrice D Cani

44 Citations (Scopus)

76 Downloads (Pure)

Abstract

OBJECTIVE: To examine the role of hepatocyte myeloid differentiation primary-response gene 88 (MyD88) on glucose and lipid metabolism.

DESIGN: To study the impact of the innate immune system at the level of the hepatocyte and metabolism, we generated mice harbouring hepatocyte-specific deletion of MyD88. We investigated the impact of the deletion on metabolism by feeding mice with a normal control diet or a high-fat diet for 8 weeks. We evaluated body weight, fat mass gain (using time-domain nuclear magnetic resonance), glucose metabolism and energy homeostasis (using metabolic chambers). We performed microarrays and quantitative PCRs in the liver. In addition, we investigated the gut microbiota composition, bile acid profile and both liver and plasma metabolome. We analysed the expression pattern of genes in the liver of obese humans developing non-alcoholic steatohepatitis (NASH).

RESULTS: Hepatocyte-specific deletion of MyD88 predisposes to glucose intolerance, inflammation and hepatic insulin resistance independently of body weight and adiposity. These phenotypic differences were partially attributed to differences in gene expression, transcriptional factor activity (ie, peroxisome proliferator activator receptor-α, farnesoid X receptor (FXR), liver X receptors and STAT3) and bile acid profiles involved in glucose, lipid metabolism and inflammation. In addition to these alterations, the genetic deletion of MyD88 in hepatocytes changes the gut microbiota composition and their metabolomes, resembling those observed during diet-induced obesity. Finally, obese humans with NASH displayed a decreased expression of different cytochromes P450 involved in bioactive lipid synthesis.

CONCLUSIONS: Our study identifies a new link between innate immunity and hepatic synthesis of bile acids and bioactive lipids. This dialogue appears to be involved in the susceptibility to alterations associated with obesity such as type 2 diabetes and NASH, both in mice and humans.

Original language	English
Journal	Gut
Volume	66
Issue number	4
Pages (from-to)	620-632
Number of pages	13
ISSN	0017-5749
DOIs	https://doi.org/10.1136/gutjnl-2015-310904
Publication status	Published - 1 Apr 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/gutjnl-2015-310904Licence: CC BY-NC

Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolismFinal published version, 3.01 MBLicence: CC BY-NC

Cite this

Duparc, T., Plovier, H., Marrachelli, V. G., Van Hul, M., Essaghir, A., Ståhlman, M., Matamoros, S., Geurts, L., Pardo-Tendero, M. M., Druart, C., Delzenne, N. M., Demoulin, J.-B., van der Merwe, S. W., van Pelt, J., Bäckhed, G. F., Monleon, D., Everard, A., & Cani, P. D. (2017). Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism. Gut, 66(4), 620-632. https://doi.org/10.1136/gutjnl-2015-310904

Duparc, T, Plovier, H, Marrachelli, VG, Van Hul, M, Essaghir, A, Ståhlman, M, Matamoros, S, Geurts, L, Pardo-Tendero, MM, Druart, C, Delzenne, NM, Demoulin, J-B, van der Merwe, SW, van Pelt, J, Bäckhed, GF, Monleon, D, Everard, A & Cani, PD 2017, 'Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism', Gut, vol. 66, no. 4, pp. 620-632. https://doi.org/10.1136/gutjnl-2015-310904

@article{c091d41d60ea4115997666e9f107001d,

title = "Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism",

abstract = "OBJECTIVE: To examine the role of hepatocyte myeloid differentiation primary-response gene 88 (MyD88) on glucose and lipid metabolism.DESIGN: To study the impact of the innate immune system at the level of the hepatocyte and metabolism, we generated mice harbouring hepatocyte-specific deletion of MyD88. We investigated the impact of the deletion on metabolism by feeding mice with a normal control diet or a high-fat diet for 8 weeks. We evaluated body weight, fat mass gain (using time-domain nuclear magnetic resonance), glucose metabolism and energy homeostasis (using metabolic chambers). We performed microarrays and quantitative PCRs in the liver. In addition, we investigated the gut microbiota composition, bile acid profile and both liver and plasma metabolome. We analysed the expression pattern of genes in the liver of obese humans developing non-alcoholic steatohepatitis (NASH).RESULTS: Hepatocyte-specific deletion of MyD88 predisposes to glucose intolerance, inflammation and hepatic insulin resistance independently of body weight and adiposity. These phenotypic differences were partially attributed to differences in gene expression, transcriptional factor activity (ie, peroxisome proliferator activator receptor-α, farnesoid X receptor (FXR), liver X receptors and STAT3) and bile acid profiles involved in glucose, lipid metabolism and inflammation. In addition to these alterations, the genetic deletion of MyD88 in hepatocytes changes the gut microbiota composition and their metabolomes, resembling those observed during diet-induced obesity. Finally, obese humans with NASH displayed a decreased expression of different cytochromes P450 involved in bioactive lipid synthesis.CONCLUSIONS: Our study identifies a new link between innate immunity and hepatic synthesis of bile acids and bioactive lipids. This dialogue appears to be involved in the susceptibility to alterations associated with obesity such as type 2 diabetes and NASH, both in mice and humans.",

author = "Thibaut Duparc and Hubert Plovier and Marrachelli, {Vannina G} and {Van Hul}, Matthias and Ahmed Essaghir and Marcus St{\aa}hlman and S{\'e}bastien Matamoros and Lucie Geurts and Pardo-Tendero, {Mercedes M} and C{\'e}line Druart and Delzenne, {Nathalie M} and Jean-Baptiste Demoulin and {van der Merwe}, {Schalk W} and {van Pelt}, Jos and B{\"a}ckhed, {Gert Fredrik} and Daniel Monleon and Amandine Everard and Cani, {Patrice D}",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/",

year = "2017",

month = apr,

day = "1",

doi = "10.1136/gutjnl-2015-310904",

language = "English",

volume = "66",

pages = "620--632",

journal = "Gut",

issn = "0017-5749",

publisher = "B M J Group",

number = "4",

}

TY - JOUR

T1 - Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism

AU - Duparc, Thibaut

AU - Plovier, Hubert

AU - Marrachelli, Vannina G

AU - Van Hul, Matthias

AU - Essaghir, Ahmed

AU - Ståhlman, Marcus

AU - Matamoros, Sébastien

AU - Geurts, Lucie

AU - Pardo-Tendero, Mercedes M

AU - Druart, Céline

AU - Delzenne, Nathalie M

AU - Demoulin, Jean-Baptiste

AU - van der Merwe, Schalk W

AU - van Pelt, Jos

AU - Bäckhed, Gert Fredrik

AU - Monleon, Daniel

AU - Everard, Amandine

AU - Cani, Patrice D

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE: To examine the role of hepatocyte myeloid differentiation primary-response gene 88 (MyD88) on glucose and lipid metabolism.DESIGN: To study the impact of the innate immune system at the level of the hepatocyte and metabolism, we generated mice harbouring hepatocyte-specific deletion of MyD88. We investigated the impact of the deletion on metabolism by feeding mice with a normal control diet or a high-fat diet for 8 weeks. We evaluated body weight, fat mass gain (using time-domain nuclear magnetic resonance), glucose metabolism and energy homeostasis (using metabolic chambers). We performed microarrays and quantitative PCRs in the liver. In addition, we investigated the gut microbiota composition, bile acid profile and both liver and plasma metabolome. We analysed the expression pattern of genes in the liver of obese humans developing non-alcoholic steatohepatitis (NASH).RESULTS: Hepatocyte-specific deletion of MyD88 predisposes to glucose intolerance, inflammation and hepatic insulin resistance independently of body weight and adiposity. These phenotypic differences were partially attributed to differences in gene expression, transcriptional factor activity (ie, peroxisome proliferator activator receptor-α, farnesoid X receptor (FXR), liver X receptors and STAT3) and bile acid profiles involved in glucose, lipid metabolism and inflammation. In addition to these alterations, the genetic deletion of MyD88 in hepatocytes changes the gut microbiota composition and their metabolomes, resembling those observed during diet-induced obesity. Finally, obese humans with NASH displayed a decreased expression of different cytochromes P450 involved in bioactive lipid synthesis.CONCLUSIONS: Our study identifies a new link between innate immunity and hepatic synthesis of bile acids and bioactive lipids. This dialogue appears to be involved in the susceptibility to alterations associated with obesity such as type 2 diabetes and NASH, both in mice and humans.

AB - OBJECTIVE: To examine the role of hepatocyte myeloid differentiation primary-response gene 88 (MyD88) on glucose and lipid metabolism.DESIGN: To study the impact of the innate immune system at the level of the hepatocyte and metabolism, we generated mice harbouring hepatocyte-specific deletion of MyD88. We investigated the impact of the deletion on metabolism by feeding mice with a normal control diet or a high-fat diet for 8 weeks. We evaluated body weight, fat mass gain (using time-domain nuclear magnetic resonance), glucose metabolism and energy homeostasis (using metabolic chambers). We performed microarrays and quantitative PCRs in the liver. In addition, we investigated the gut microbiota composition, bile acid profile and both liver and plasma metabolome. We analysed the expression pattern of genes in the liver of obese humans developing non-alcoholic steatohepatitis (NASH).RESULTS: Hepatocyte-specific deletion of MyD88 predisposes to glucose intolerance, inflammation and hepatic insulin resistance independently of body weight and adiposity. These phenotypic differences were partially attributed to differences in gene expression, transcriptional factor activity (ie, peroxisome proliferator activator receptor-α, farnesoid X receptor (FXR), liver X receptors and STAT3) and bile acid profiles involved in glucose, lipid metabolism and inflammation. In addition to these alterations, the genetic deletion of MyD88 in hepatocytes changes the gut microbiota composition and their metabolomes, resembling those observed during diet-induced obesity. Finally, obese humans with NASH displayed a decreased expression of different cytochromes P450 involved in bioactive lipid synthesis.CONCLUSIONS: Our study identifies a new link between innate immunity and hepatic synthesis of bile acids and bioactive lipids. This dialogue appears to be involved in the susceptibility to alterations associated with obesity such as type 2 diabetes and NASH, both in mice and humans.

U2 - 10.1136/gutjnl-2015-310904

DO - 10.1136/gutjnl-2015-310904

M3 - Journal article

C2 - 27196572

SN - 0017-5749

VL - 66

SP - 620

EP - 632

JO - Gut

JF - Gut

IS - 4

ER -

Hepatocyte MyD88 affects bile acids, gut microbiota and metabolome contributing to regulate glucose and lipid metabolism

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this